We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01141959
Recruitment Status : Completed
First Posted : June 11, 2010
Last Update Posted : March 10, 2015
Sponsor:
Collaborator:
Information provided by (Responsible Party):

June 8, 2010
June 11, 2010
March 10, 2015
May 2010
December 2011   (Final data collection date for primary outcome measure)
Donor T-cell chimerism [ Time Frame: Day 28 post-transplant ]
Same as current
Complete list of historical versions of study NCT01141959 on ClinicalTrials.gov Archive Site
Exposure to cyclophosphamide, fludarabine, and mycophenolate mofetil and their breakdown products [ Time Frame: 1 week before through 3 weeks after transplant ]
Same as current
Not Provided
Not Provided
 
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients
The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
plasma, DNA
Non-Probability Sample
Hematopoeitic cell transplant patients with haploidentical donors receiving cyclophosphamide, fludarabine and mycophenolate mofetil.
  • Leukemia
  • Hodgkin Disease
  • Non-Hodgkin Lymphoma
  • Myelodysplastic Syndrome
  • Multiple Myeloma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
11
December 2011
December 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Scheduled to receive nonmyeloablative conditioning which includes fludarabine
  • Scheduled to receive a haploidentical graft
  • Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate mofetil (MMF) or enteric-coated mycophenolic acid
  • Age >18 years at the time of enrollment

Exclusion Criteria:

  • Diagnosed with an immunodeficiency disorder, including HIV
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01141959
FHCRC-2373.00
IR-7093 ( Other Identifier: FHCRC )
R01HL091744-02S1 ( U.S. NIH Grant/Contract )
No
Not Provided
Not Provided
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: Jeannine McCune, PharmD Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center
March 2015